IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by PNC Financial Services Group Inc.

PNC Financial Services Group Inc. reduced its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 1.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 49,636 shares of the medical research company’s stock after selling 728 shares during the period. PNC Financial Services Group Inc.’s holdings in IQVIA were worth $9,754,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the company. Capital Performance Advisors LLP bought a new position in IQVIA during the third quarter worth $27,000. Synergy Asset Management LLC bought a new position in IQVIA during the fourth quarter worth $33,000. Avior Wealth Management LLC lifted its stake in IQVIA by 117.6% during the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after purchasing an additional 87 shares during the last quarter. Assetmark Inc. lifted its stake in IQVIA by 612.5% during the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock worth $54,000 after purchasing an additional 196 shares during the last quarter. Finally, Ashton Thomas Securities LLC bought a new position in IQVIA during the third quarter worth $57,000. 89.62% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts recently issued reports on IQV shares. Robert W. Baird reduced their price objective on IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 21st. Morgan Stanley raised their target price on IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a research note on Tuesday, February 11th. William Blair reiterated an “outperform” rating on shares of IQVIA in a research note on Wednesday, December 11th. Truist Financial reiterated a “buy” rating and issued a $263.00 target price (up from $261.00) on shares of IQVIA in a research note on Monday, February 10th. Finally, Bank of America cut their target price on IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a research note on Friday, December 13th. Five equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $249.05.

IQVIA Trading Down 2.7 %

Shares of IQV stock opened at $183.72 on Wednesday. The stock has a 50-day simple moving average of $197.36 and a 200 day simple moving average of $211.78. The stock has a market capitalization of $32.39 billion, a P/E ratio of 24.50, a P/E/G ratio of 1.99 and a beta of 1.50. IQVIA Holdings Inc. has a fifty-two week low of $179.28 and a fifty-two week high of $261.72. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, sell-side analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.